Drug Trial Radar · NCT07006792
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
233
Actual
Start
Jun 16, 2025
Primary completion
May 14, 2026
Study completion Sep 21, 2026
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jun 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure how well taking lebrikizumab alone works for participants with fewer places on the body with eczema (atopic dermatitis), but these places may be very itchy. Participation in this study will last up to approximately 38 weeks (9 and a half months) including 24 weeks (6 months) of treatment.
Conditions
- Atopic Dermatitis
Interventions
LebrikizumabDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) (≥75% Reduction from Baseline in EASI), or a ≥4-point Reduction in Pruritus Numerical Rating Scale (NRS) from BaselineTime frame: Week 16
Locations
66 sites in 5 countries. Site status is shown where the registry gives one.
Total Skin & Beauty Dermatology Center, PC DBA Total Dermatology
Birmingham, Alabama
Research Solutions of Arizona
Litchfield Park, Arizona
Alliance Dermatology and Mohs Center
Phoenix, Arizona
California Dermatology & Clinical Research Institute
Encinitas, California
Dermatology Research Associates
Los Angeles, California
NorCal Clinical Research
Rocklin, California
Suncoast Research Associates
Doral, Florida
Encore Medical Research
Hollywood, Florida
Solutions Through Advanced Research
Jacksonville, Florida
Life Arc Research Centers - Miami
Miami, Florida
MCR Research
Miami, Florida
Health Clinical Research
Miami, Florida
Deluxe Health Center
Miami Lakes, Florida
Renstar Medical Research
Ocala, Florida
Leading Edge Dermatology
Plantation, Florida
Dermatology Affiliates Research Institute
Atlanta, Georgia
DeNova Research
Chicago, Illinois
Southern Indiana Clinical Research Center
Columbus, Indiana
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
Southern Indiana Clinical Trials
New Albany, Indiana
Equity Medical - Bowling Green
Bowling Green, Kentucky
Allergy & Asthma Specialists, P.S.C.
Owensboro, Kentucky
Foxhall Research Center
Chevy Chase, Maryland
Great Lakes Research Group, Inc.
Bay City, Michigan
Revival Research Institute, LLC
Troy, Michigan
Albuquerque Clinical Trials, Inc.
Albuquerque, New Mexico
Equity Medical
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Hickory Dermatology Research Center
Hickory, North Carolina
ObjectiveHealth - Goodlettsville Dermatology Research
Goodlettsville, Tennessee
Reveal Research Institute - Frisco
Frisco, Texas
Biopharma Informatic, LLC
Houston, Texas
Prime Clinical Research - Mansfield
Mansfield, Texas
Texas Dermatology and Laser Specialists - San Antonio - South New Braunfels Avenue
San Antonio, Texas
Jordan Valley Dermatology & Research Center
South Jordan, Utah
CONEXA Investigacion Clinica S.A.
Buenos Aires, Argentina
CIPREC
Buenos Aires, Argentina
Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, Argentina
DOM Centro de Reumatología
Buenos Aires, Argentina
Instituto de Neumonologia Y Dermatologia
Buenos Aires, Argentina
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.